nach oben

Archivum Immunologiae et Therapiae Experimentalis

Erschienen in:

01.12.2023 | Review

Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer

verfasst von: Yu Cao, Sergey K. Efetov, Mingze He, Yu Fu, Narasimha M. Beeraka, Jin Zhang, Xinliang Zhang, Namitha Bannimath, Kuo Chen

Erschienen in: Archivum Immunologiae et Therapiae Experimentalis | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has increased worldwide and caused a higher mortality rate due to the lack of selective anti-tumor therapies. Current chemotherapies and surgical interventions are significantly preferred modalities to treat CRC or BC in advanced stages but the prognosis for patients with advanced CRC and BC remains dismal. The immunotherapy technique of chimeric antigen receptor (CAR)-T cells has resulted in significant clinical outcomes when treating hematologic malignancies. The novel CAR-T therapy target antigens include GUCY2C, CLEC14A, CD26, TEM8/ANTXR1, PDPN, PTK7, PODXL, CD44, CD19, CD20, CD22, BCMA, GD2, Mesothelin, TAG-72, CEA, EGFR, B7H3, HER2, IL13Ra2, MUC1, EpCAM, PSMA, PSCA, NKG2D. The significant aim of this review is to explore the recently updated information pertinent to several novel targets of CAR-T for CRC, and BC. We vividly described the challenges of CAR-T therapies when treating CRC or BC. The immunosuppressive microenvironment of solid tumors, the shortage of tumor-specific antigens, and post-treatment side effects are the major hindrances to promoting the development of CAR-T cells. Several clinical trials related to CAR-T immunotherapy against CRC or BC have already been in progress. This review benefits academicians, clinicians, and clinical oncologists to explore more about the novel CAR-T targets and overcome the challenges during this therapy.

Vorheriger Artikel In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy

Nächster Artikel Improved Production of Anti-FGF-2 Nanobody Using Pichia pastoris and Its Effect on Antiproliferation of Keratinocytes and Alleviation of Psoriasis

Ahn JC, Teng PC, Chen PJ et al (2021) Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology 73:422–436. https://doi.org/10.1002/hep.31165CrossRefPubMed

Amatya C, Pegues MA, Lam N et al (2021) Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7. Mol Ther 29:702–717. https://doi.org/10.1016/j.ymthe.2020.10.008CrossRefPubMed

Aoe T, Goto S, Ohno H et al (1994) Different cytoplasmic structure of the CD3ζ family dimer modulates the activation signal and function of T cells. Int Immunol 6:1671–1679. https://doi.org/10.1093/intimm/6.11.1671CrossRefPubMed

Baybutt T, Snook A, Waldman S et al (2020) 105 A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy. J Immunother Cancer 8(Suppl 3):A116–A116. https://doi.org/10.1136/jitc-2020-SITC2020.0105CrossRef

Boice M, Salloum D, Mourcin F et al (2016) Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell 167:405–418. https://doi.org/10.1016/j.cell.2016.08.032CrossRefPubMedPubMedCentral

Bridgeman JS, Hawkins RE, Bagley S et al (2010) The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 184:6938–6949. https://doi.org/10.4049/jimmunol.0901766CrossRefPubMed

Brown TC, Sankpal NV, Gillanders WE (2021) Functional implications of the dynamic regulation of EpCAM during epithelial-to-mesenchymal transition. Biomolecules 11:956. https://doi.org/10.3390/biom11070956CrossRefPubMedPubMedCentral

Budi HS, Ahmad FN, Achmad H et al (2022) Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress. Stem Cell Res Ther 13:1–21. https://doi.org/10.1186/s13287-022-02719-0CrossRef

Burga RA, Thorn M, Point GR et al (2015) Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 64:817–829. https://doi.org/10.1007/s00262-015-1692-6CrossRefPubMedPubMedCentral

Carney WP, Leitzel K, Ali S et al (2007) HER-2 therapy. HER-2/neu diagnostics in breast cancer. Breast Cancer Res 9:207. https://doi.org/10.1186/bcr1664CrossRefPubMedPubMedCentral

Cerrano M, Ruella M, Perales MA et al (2020) The advent of CAR T-cell therapy for lymphoproliferative neoplasms: integrating research into clinical practice. Front Immunol 11:888. https://doi.org/10.3389/fimmu.2020.00888CrossRefPubMedPubMedCentral

Cha SE, Kujawski M, Yazaki PJ et al (2021) Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Oncoimmunology 10:1899469. https://doi.org/10.1080/2162402X.2021.1899469CrossRefPubMedPubMedCentral

Chen N, Morello A, Tano Z et al (2017) CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy. Oncoimmunology 6:e1273302. https://doi.org/10.1080/2162402X.2016.1273302CrossRefPubMed

Chmielewski M, Abken H (2015) TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15:1145–1154. https://doi.org/10.1517/14712598.2015.1046430CrossRefPubMed

Cho J, Kim KM, Kim HC et al (2019) The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. Pathol Res Pract 215:171–176. https://doi.org/10.1016/j.prp.2018.10.024CrossRefPubMed

Corti C, Venetis K, Sajjadi E et al (2022) CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opin Investig Drugs 31:593–605. https://doi.org/10.1080/13543784.2022.2054326CrossRefPubMed

Cruz-Duarte R, Rebelo de Almeida C, Negrão M et al (2022) Predictive and therapeutic implications of a novel PLCγ1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancerPLCγ1: clinical implications for cetuximab therapy. Clin Cancer Res 28:1203–1216. https://doi.org/10.1158/1078-0432.CCR-21-1992CrossRefPubMedPubMedCentral

D’Aloia MM, Zizzari IG, Sacchetti B et al (2018) CAR-T cells: the long and winding road to solid tumors. Cell Death Dis 9:282. https://doi.org/10.1038/s41419-018-0278-6CrossRefPubMedPubMedCentral

Donnadieu E, Dupré L, Pinho LG et al (2020) Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. J Leukoc Biol 108:1067–1079. https://doi.org/10.1002/JLB.1MR0520-746RCrossRefPubMed

Drago JZ, Ferraro E, Abuhadra N et al (2022) Beyond HER2: targeting the ErbB receptor family in breast cancer. Cancer Treat Rev 109:102436. https://doi.org/10.1016/j.ctrv.2022.102436CrossRefPubMedPubMedCentral

Fakih MG, Padmanabhan A (2006) CEA monitoring in colorectal cancer. What you should know. Oncology 20:579–587. https://europepmc.org/article/med/16773844

Fan J, Das JK, Xiong X et al (2021) Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors. Front Oncol 10:574860. https://doi.org/10.3389/fonc.2020.574860CrossRefPubMedPubMedCentral

Faust JR, Hamill D, Kolb EA et al (2022) Mesothelin: An immunotherapeutic target beyond solid tumors. Cancers 14:1550. https://doi.org/10.3390/cancers14061550CrossRefPubMedPubMedCentral

Fesnak AD, June VH, Levine BL (2016) Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 16:566–581. https://doi.org/10.1038/nrc.2016.97CrossRefPubMedPubMedCentral

Fong D, Moser P, Kasal A et al (2014) Loss of membranous expression of the intracellular domain of Ep CAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology 64:683–692. https://doi.org/10.1111/his.12307CrossRefPubMed

Fournier C, Martin F, Zitvogel L et al (2017) Trial watch: adoptively transferred cells for anticancer immunotherapy. Oncoimmunology 6:e1363139. https://doi.org/10.1080/2162402X.2017.1363139CrossRefPubMedPubMedCentral

Freed DM, Bessman NJ, Kiyatkin A et al (2017) EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell 171:683–695. https://doi.org/10.1016/j.cell.2017.09.017CrossRefPubMedPubMedCentral

Gay F, D’Agostino M, Giaccone L et al (2017) Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors. Clin Lymphoma Myeloma Leuk 17:471–478. https://doi.org/10.1016/j.clml.2017.06.014CrossRefPubMed

Ghazi B, El Ghanmi A, Kandoussi S et al (2022) CAR T-cells for colorectal cancer immunotherapy: ready to go? Front Immunol 13:978195. https://doi.org/10.3389/fimmu.2022.978195CrossRefPubMedPubMedCentral

Globerson-Levin A, Waks T, Eshhar Z (2014) Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther 22:1029–1038. https://doi.org/10.1038/mt.2014.28CrossRefPubMedPubMedCentral

Golubovskaya VM, Berahovich R, Zhou H et al (2020) PLAP (placental alkaline phosphatase)-CAR-T cells specifically target colorectal cancer. Cancer Res 80(16_Suppl):4228–4228. https://doi.org/10.1158/1538-7445.AM2020-4228CrossRef

Guedan S, Posey AD Jr, Shaw C et al (2018) Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3:e96976. https://doi.org/10.1172/jci.insight.96976CrossRefPubMedPubMedCentral

Guedan S, Calderon H, Posey AD Jr et al (2019) Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev 12:145–156. https://doi.org/10.1016/j.omtm.2018.12.009CrossRefPubMed

Guizhen Z, Guanchang J, Liwen L et al (2022) The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy. Front Endocrinol 13:918869. https://doi.org/10.3389/fendo.2022.918869CrossRef

Hagemann UB, Ellingsen C, Schuhmacher J et al (2019) Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers MSLN-targeted thorium-227 conjugate. Clin Cancer Res 25:4723–4734. https://doi.org/10.1158/1078-0432.CCR-18-3476CrossRefPubMed

Hauck W, Stanners CP (1991) Control of carcinoembryonic antigen gene family expression in a differentiating colon carcinoma cell line, Caco-2. Cancer Res 51:3526–3533 (51/13/3526/2443891/cr0510133526)PubMed

He Y, Wang X (2020) Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis. Ann Transl Med 8:1050. https://doi.org/10.21037/atm-20-922CrossRefPubMedPubMedCentral

Hege KM, Bergsland EK, Fisher GA et al (2017) Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer 5:22. https://doi.org/10.1186/s40425-017-0222-9CrossRefPubMedPubMedCentral

Holzinger A, Abken H (2017) CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target. Cancer Immunol Immunother 66:1505–1507. https://doi.org/10.1007/s00262-017-2045-4CrossRefPubMed

Hombach AA, Rappl G, Abken H (2019) Blocking CD30 on T cells by a dual specific CAR for CD30 and colon cancer antigens improves the CAR T cell response against CD30⁻ tumors. Mol Ther 27:1825–1835. https://doi.org/10.1016/j.ymthe.2019.06.007CrossRefPubMedPubMedCentral

Hou X, Wang F, Meng X et al (2022) Construction of a 124I-labeled specific antibody for the noninvasive detection of mesothelin-overexpressing tumors. Mol Pharm 19:3623–3631. https://doi.org/10.1021/acs.molpharmaceut.2c00342CrossRefPubMed

Hsu HJ, Tung CP, Yu CM et al (2021) Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries. Sci Rep 11:15430. https://doi.org/10.1038/s41598-021-94902-1CrossRefPubMedPubMedCentral

Hu B, Zou Y, Zhang L et al (2019) Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum Gene Ther 30:446–458. https://doi.org/10.1089/hum.2017.234CrossRefPubMed

Huang R, Li X, He Y et al (2020a) Recent advances in CAR-T cell engineering. J Hematol Oncol 13:86. https://doi.org/10.1186/s13045-020-00910-5CrossRefPubMedPubMedCentral

Huang Y, Li D, Zhang PF et al (2020b) IL-18R-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells. FASEB J 34:1768–1782. https://doi.org/10.1096/fj.201901809RCrossRefPubMed

Hudecek M, Sommermeyer D, Kosasih PL et al (2015) The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 3:125–135. https://doi.org/10.1158/2326-6066.CIR-14-0127CrossRefPubMed

Hwu P, Shafer G, Treisman J et al (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 178:361–366. https://doi.org/10.1084/jem.178.1.361CrossRefPubMed

Hwu P, Yang J, Cowherd R et al (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369–3373 (55/15/3369/2457347/cr0550153369)PubMed

Hyrenius-Wittsten A, Su Y, Park M et al (2021) SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med 13:eabd8836. https://doi.org/10.1126/scitranslmed.abd8836CrossRefPubMedPubMedCentral

John LB, Devaud C, Duong CP et al (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells anti-PD-1 therapy enhances tumor rejection by CAR T cells. Clin Cancer Res 19:5636–5646. https://doi.org/10.1158/1078-0432.CCR-13-0458CrossRefPubMed

Jones S, Rappoport JZ (2014) Interdependent epidermal growth factor receptor signalling and trafficking. Int J Biochem Cell Biol 51:23–28. https://doi.org/10.1016/j.biocel.2014.03.014CrossRefPubMed

June CH, O’Connor RS, Kawalekar OU et al (2018) CAR T cell immunotherapy for human cancer. Science 359:1361–1365. https://doi.org/10.1126/science.aar6711CrossRefPubMed

Kagoya Y, Tanaka S, Guo T et al (2018) A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects. Nat Med 24:352–359. https://doi.org/10.1038/nm.4478CrossRefPubMedPubMedCentral

Katz SC, Burga RA, McCormack E et al (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor–modified T-cell therapy for CEA+ liver metastases hepatic artery CAR-T infusions. Clin Cancer Res 21:3149–3159. https://doi.org/10.1158/1078-0432.CCR-14-1421CrossRefPubMedPubMedCentral

Katz SC, Hardaway J, Prince E et al (2020) HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Ther 27:341–355. https://doi.org/10.1038/s41417-019-0104-zCrossRefPubMed

Keshavarz A, Salehi A, Khosravi S et al (2022) Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. Stem Cell Res Ther 13:482. https://doi.org/10.1186/s13287-022-03163-wCrossRefPubMedPubMedCentral

Knödler M, Körfer J, Kunzmann V et al (2018) Randomised phase II trial to investigate catumaxomab (anti-EpCAM× anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer 119:296–302. https://doi.org/10.1038/s41416-018-0150-6CrossRefPubMedPubMedCentral

Kotch C, Barrett D, Teachey DT (2019) Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 15:813–822. https://doi.org/10.1080/1744666X.2019.1629904CrossRefPubMedPubMedCentral

Kozani PS, Kozani PS, Rahbarizadeh F (2021) Novel antigens of CAR T cell therapy: new roads; old destination. Transl Oncol 14:101079. https://doi.org/10.1016/j.tranon.2021.101079CrossRef

Kremer V, Ligtenberg MA, Zendehdel R et al (2017) Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J Immunother Cancer 5:73. https://doi.org/10.1186/s40425-017-0275-9CrossRefPubMedPubMedCentral

Kumar V, Abbas AK, Aster JC (2017) Robbins basic pathology e-book. Elsevier, New York. https://doi.org/10.1093/ajcp/aqx095CrossRef

Lech G, Słotwiński R, Słodkowski M et al (2016) Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World J Gastroenterol 22:1745. https://doi.org/10.3748/wjg.v22.i5.1745CrossRefPubMedPubMedCentral

Levitsky K, Li Z, Pham MT et al (2020) Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors. Cancer Res 80(16_Suppl):3243–3243. https://doi.org/10.1158/1538-7445.AM2020-3243CrossRef

Li J, Han X, Yu X et al (2018) Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res 37:213. https://doi.org/10.1186/s13046-018-0893-1CrossRefPubMedPubMedCentral

Li X, Berahovich R, Zhou H et al (2020a) PLAP-CAR T cells mediate high specific cytotoxicity against colon cancer cells. Front Biosci 25:1765–1786. https://doi.org/10.2741/4877CrossRef

Li Y, Xiao F, Zhang A et al (2020b) Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. Cell Immunol 348:104041. https://doi.org/10.1016/j.cellimm.2020.104041CrossRefPubMed

Li Z, Chi Z, Ang WX et al (2020c) Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR. Immunotherapy 12:733–748. https://doi.org/10.2217/imt-2019-0137CrossRefPubMed

Liao MY, Lai JK, Kuo MYP et al (2015) An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget 6:24947. https://doi.org/10.18632/oncotarget.4453CrossRefPubMedPubMedCentral

Lim WA, June CH (2017) The principles of engineering immune cells to treat cancer. Cell 168:724–740. https://doi.org/10.1016/j.cell.2017.01.016CrossRefPubMedPubMedCentral

Lipowska-Bhalla G, Gilham DE, Hawkins RE et al (2012) Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother 61:953–962. https://doi.org/10.1007/s00262-012-1254-0CrossRefPubMed

Liu B, Yan L, Zhou M (2019) Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J Cancer Res 9:228 (ajcr0090440)PubMedPubMedCentral

Liu G, Rui W, Zheng H et al (2020) CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol 50:712–724. https://doi.org/10.1002/eji.201948457CrossRefPubMed

Liu G, Zhang Q, Li D et al (2021a) PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Hum Immunol 82:130–138. https://doi.org/10.1016/j.humimm.2020.12.002CrossRefPubMed

Liu G, Zhang Q, Liu G et al (2021b) Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo. Exp Cell Res 409:112886. https://doi.org/10.1016/j.yexcr.2021.112886CrossRefPubMed

Lloyd A, Vickery ON, Laugel B (2013) Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol 4:221. https://doi.org/10.3389/fimmu.2013.00221CrossRefPubMedPubMedCentral

Lu J, Jiang G (2022) The journey of CAR-T therapy in hematological malignancies. Mol Cancer 21:194. https://doi.org/10.1186/s12943-022-01663-0CrossRefPubMedPubMedCentral

Ma X, Shou P, Smith C et al (2020) Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol 38:448–459. https://doi.org/10.1038/s41587-019-0398-2CrossRefPubMedPubMedCentral

Magee MS, Kraft CL, Abraham TS et al (2016) GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology 5:e1227897. https://doi.org/10.1080/2162402X.2016.1227897CrossRefPubMedPubMedCentral

Magee MS, Abraham TS, Baybutt TR et al (2018) Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases CAR-T cells target human GUCY2C+ colorectal tumors. Cancer Immunol Res 6:509–516. https://doi.org/10.1158/2326-6066.CIR-16-0362CrossRefPubMedPubMedCentral

Majzner RG, Ramakrishna S, Yeom KW et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603:934–941. https://doi.org/10.1038/s41586-022-04489-4CrossRefPubMedPubMedCentral

Marei HE, Althani A, Caceci T et al (2019) Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: preclinical evidence versus clinical outcomes. Biochem Pharmacol 166:335–346. https://doi.org/10.1016/j.bcp.2019.06.002CrossRefPubMed

Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128. https://doi.org/10.3389/fimmu.2019.00128CrossRefPubMedPubMedCentral

Martínez-Lago N, Chucla TC, De Castro BA et al (2022) Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep 12:14612. https://doi.org/10.1038/s41598-022-18871-9CrossRefPubMedPubMedCentral

Masoumi E, Jafarzadeh L, Mirzaei HR et al (2020) Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells. J Exp Clin Cancer Res 39:49. https://doi.org/10.1186/s13046-020-01546-6CrossRefPubMedPubMedCentral

McGowan E, Lin Q, Ma G et al (2020) PD-1 disrupted CAR-T cells in the treatment of solid tumors: promises and challenges. Biomed Pharmacother 121:109625. https://doi.org/10.1016/j.biopha.2019.109625CrossRefPubMed

Minnix M, Li L, Yazaki P et al (2020) Improved targeting of an anti-TAG-72 antibody drug conjugate for the treatment of ovarian cancer. Cancer Med 9:4756–4767. https://doi.org/10.1002/cam4.3078CrossRefPubMedPubMedCentral

Mishra V, Bose A, Kiran S et al (2021) Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C. J Exp Med 218:e2021047. https://doi.org/10.1084/jem.20210479CrossRef

Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469–6487. https://doi.org/10.1038/sj.onc.1210477CrossRefPubMedPubMedCentral

Moghimi B, Muthugounder S, Jambon S et al (2021) Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun 12:511. https://doi.org/10.1038/s41467-020-20785-xCrossRefPubMedPubMedCentral

Moon DH, Lindsay DP, Hong S et al (2018) Clinical indications for, and the future of, circulating tumor cells. Adv Drug Deliv Rev 125:143–150. https://doi.org/10.1016/j.addr.2018.04.002CrossRefPubMed

Morgan RA, Yang JC, Kitano M et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843–851. https://doi.org/10.1038/mt.2010.24CrossRefPubMedPubMedCentral

Mount CW, Majzner RG, Sundaresh S et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med 24:572–579. https://doi.org/10.1038/s41591-018-0006-xCrossRefPubMedPubMedCentral

Mullard A (2021) FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov 20:332. https://doi.org/10.1038/d41573-021-00063-1CrossRefPubMed

Munshi NC, Anderson LD Jr, Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384:705–716. https://doi.org/10.1056/NEJMoa2024850CrossRefPubMed

Nalawade SA, Shafer P, Bajgain P et al (2021) Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer 9:e003237. https://doi.org/10.1136/jitc-2021-003237CrossRefPubMedPubMedCentral

Nasiri F, Kazemi M, Mirarefin SMJ et al (2022) CAR-T cell therapy in triple-negative breast cancer: hunting the invisible devil. Front Immunol 13:1018786. https://doi.org/10.3389/fimmu.2022.1018786CrossRefPubMedPubMedCentral

Nathanson DR, Culliford AT IV, Shia J et al (2003) HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105:796–802. https://doi.org/10.1002/ijc.11137CrossRefPubMed

Neelapu SS (2019) Managing the toxicities of car T-cell therapy. Hematol Oncol 37:48–52. https://doi.org/10.1002/hon.2595CrossRefPubMed

Newick K, Moon E, Albelda SM (2016) Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics 3:16006. https://doi.org/10.1038/mto.2016.6CrossRefPubMedPubMedCentral

Newick K, O’Brien S, Moon E et al (2017) CAR T cell therapy for solid tumors. Annu Rev Med 68:139–152. https://doi.org/10.1146/annurev-med-062315-120245CrossRefPubMed

Nishimoto N, Terao K, Mima T et al (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959–3964. https://doi.org/10.1182/blood-2008-05-155846CrossRefPubMed

Niv Y (2008) MUC1 and colorectal cancer pathophysiology considerations. World J Gastroenterol 14:2139. https://doi.org/10.3748/wjg.14.2139CrossRefPubMedPubMedCentral

Orning P, Lien E, Fitzgerald KA (2019) Gasdermins and their role in immunity and inflammation. J Exp Med 216:2453–2465. https://doi.org/10.1084/jem.20190545CrossRefPubMedPubMedCentral

Ouyang M, Wu W, Zou Y et al (2010) Immunoreactivity and prognostic value of tumor-associated glycoprotein 72 in primary gallbladder carcinoma. Surg Oncol 19:82–87. https://doi.org/10.1016/j.suronc.2009.03.010CrossRefPubMed

Oved JH, Barrett DM, Teachey DT (2019) Cellular therapy: immune-related complications. Immunol Rev 290:114–126. https://doi.org/10.1111/imr.12768CrossRefPubMedPubMedCentral

Owen K, Ghaly R, Shohdy KS et al (2022) Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis. Cancer Immunol Immunother 72:805–814. https://doi.org/10.1007/s00262-022-03287-1CrossRefPubMedPubMedCentral

Patel JM, Dale GA, Vartabedian VF et al (2014) Cancer CARtography: charting out a new approach to cancer immunotherapy. Immunotherapy 6:675–678. https://doi.org/10.2217/imt.14.44CrossRefPubMed

Patriarca C, Macchi RM, Marschner AK et al (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38:68–75. https://doi.org/10.1016/j.ctrv.2011.04.002CrossRefPubMed

Pattison AM, Merlino DJ, Blomain ES et al (2016) Guanylyl cyclase C signaling axis and colon cancer prevention. World J Gastroenterol 22:8070. https://doi.org/10.3748/wjg.v22.i36.8070CrossRefPubMedPubMedCentral

Pehlivan KC, Duncan BB, Lee DW (2018) CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Curr Hematol Malignancy Rep 13:396–406. https://doi.org/10.1007/s11899-018-0470-xCrossRef

Peterse EF, Meester RG, Siegel RL et al (2018) The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer 124:2964–2973. https://doi.org/10.1002/cncr.31543CrossRefPubMed

Pfeifer R (2018) Evaluation of SSEA-4 as a CAR T cell therapeutic target for the treatment of chemoresistant triple negative breast cancers. Universität Tübingen, Tübingen. https://doi.org/10.15496/publikation-26519CrossRef

Prasad V (2018) Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol 15:11–12. https://doi.org/10.1038/nrclinonc.2017.156CrossRefPubMed

Qin X, Wu F, Chen C et al (2022) Recent advances in CAR-T cells therapy for colorectal cancer. Front Immunol 13:904137. https://doi.org/10.3389/fimmu.2022.904137CrossRefPubMedPubMedCentral

Qu C, Zhang H, Cao H et al (2022) Tumor buster—where will the CAR-T cell therapy ‘missile’ go? Mol Cancer 21:201. https://doi.org/10.1186/s12943-022-01669-8CrossRefPubMedPubMedCentral

Rahbarizadeh F, Ahmadvand D, Moghimi S (2019) CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev 141:41–46. https://doi.org/10.1016/j.addr.2019.04.006CrossRefPubMed

Rizeq B, Zakaria Z, Ouhtit A (2018) Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression. Cancer Sci 109:33–42. https://doi.org/10.1111/cas.13437CrossRefPubMedPubMedCentral

Rupp LJ, Schumann K, Roybal KT et al (2017) CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 7:737. https://doi.org/10.4049/jimmunol.196.Supp.214.24CrossRefPubMedPubMedCentral

Sachdev J, Maitland M, Sharma M et al (2016) A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA). Ann Oncol 27:vi570. https://doi.org/10.1093/annonc/mdw435.29CrossRef

Sadelain M, Rivière I, Brentjens R (2003) Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3:35–45. https://doi.org/10.1038/nrc971CrossRefPubMed

Sahm C, Schönfeld K, Wels WS (2012) Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 61:1451–1461. https://doi.org/10.1007/s00262-012-1212-xCrossRefPubMed

Schepisi G, Gianni C, Palleschi M et al (2023) The new frontier of immunotherapy: chimeric antigen receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast cancer. Cancers 15:1597. https://doi.org/10.3390/cancers15051597CrossRefPubMedPubMedCentral

Schmidts A, Maus MV (2018) Making CAR T cells a solid option for solid tumors. Front Immunol 9:2593. https://doi.org/10.3389/fimmu.2018.02593CrossRefPubMedPubMedCentral

Schubert ML, Schmitt M, Wang L et al (2021) Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 32:34–48. https://doi.org/10.1016/j.annonc.2020.10.478CrossRefPubMed

Seeber A, Untergasser G, Spizzo G et al (2016) Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer. Int J Cancer 139:657–663. https://doi.org/10.1002/ijc.30099CrossRefPubMed

Sertesen E, Yekedüz E, Köksoy EB et al (2022) The effect of primary tumour resection on patients with synchronous metastatic colorectal cancer treated with cetuximab containing regimens. ANZ J Surg 93:945–950. https://doi.org/10.1111/ans.18117CrossRefPubMed

Shah NN, Fry TJ (2019) Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 16:372–385. https://doi.org/10.1038/s41571-019-0184-6CrossRefPubMedPubMedCentral

Shao D, Li J, Xiao X et al (2014) Real-time visualizing and tracing of HSV-TK/GCV suicide gene therapy by near-infrared fluorescent quantum dots. ACS Appl Mater Interfaces 6:11082–11090. https://doi.org/10.1021/am503998xCrossRefPubMed

Sheykhhasan M, Manoochehri H, Dama P (2022) Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther 29:1080–1096. https://doi.org/10.1038/s41417-021-00418-1CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551CrossRefPubMed

Singh H, Figliola MJ, Dawson MJ et al (2011) Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignanciesreprogramming CAR+ T cells with IL-21. Cancer Res 71:3516–3527. https://doi.org/10.1158/0008-5472.CAN-10-3843CrossRefPubMedPubMedCentral

Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712. https://doi.org/10.1126/science.2470152CrossRefPubMed

Srivastava S, Salter AI, Liggitt D et al (2019) Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35:489–503. https://doi.org/10.1016/j.ccell.2019.02.003CrossRefPubMedPubMedCentral

Stancovski I, Schindler D, Waks T et al (1993) Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151:6577–6582. https://doi.org/10.4049/jimmunol.151.11.6577CrossRefPubMed

Sterner RM, Sakemura R, Cox MJ et al (2019) GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133:697–709. https://doi.org/10.1182/blood-2018-10-881722CrossRefPubMedPubMedCentral

Subklewe M, von Bergwelt-Baildon M, Humpe A (2019) Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus Med Hemother 46:15–24. https://doi.org/10.1159/000496870CrossRefPubMedPubMedCentral

Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Szöőr Á, Tóth G, Zsebik B et al (2020) Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett 484:1–8. https://doi.org/10.1016/j.canlet.2020.04.008CrossRefPubMed

Teng R, Zhao J, Zhao Y et al (2019) Chimeric antigen receptor-modified T cells repressed solid tumors and their relapse in an established patient-derived colon carcinoma xenograft model. J Immunother 42:33. https://doi.org/10.1097/CJI.0000000000000251CrossRefPubMed

Thistlethwaite FC, Gilham DE, Guest RD et al (2017) The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother 66:1425–1436. https://doi.org/10.1007/s00262-017-2034-7CrossRefPubMedPubMedCentral

Tokarew N, Ogonek J, Endres S et al (2019) Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 120:26–37. https://doi.org/10.1038/s41416-018-0325-1CrossRefPubMed

Tóth G, Szöllősi J, Abken H et al (2020) A small number of HER2 redirected CAR T cells significantly improves immune response of adoptively transferred mouse lymphocytes against human breast cancer xenografts. Int J Mol Sci 21:1039. https://doi.org/10.3390/ijms21031039CrossRefPubMedPubMedCentral

Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422. https://doi.org/10.1093/annonc/mdw235CrossRefPubMed

Vasaikar SV, Straub P, Wang J et al (2018) LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 46(D1):D956–D963. https://doi.org/10.1093/nar/gkx1090CrossRefPubMed

Verhoeven Y, Tilborghs S, Jacobs H et al (2020) The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol 60:41–56. https://doi.org/10.1016/j.semcancer.2019.10.002CrossRefPubMed

Voelker R (2020) CAR-T therapy is approved for mantle cell lymphoma. JAMA 324:832–832. https://doi.org/10.1016/j.semcancer.2019.10.002CrossRefPubMed

Voldborg BR, Damstrup L, Spang-Thomsen M et al (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197–1206. https://doi.org/10.1023/A:1008209720526CrossRefPubMed

Vora P, Venugopal C, Salim SK et al (2020) The rational development of CD133-targeting immunotherapies for glioblastoma. Cell Stem Cell 26:832–844. https://doi.org/10.1016/j.stem.2020.04.008CrossRefPubMed

Wagener C, Hain F, Födisch HJ et al (1983) Localisation of carcinoembryonic antigen in embryonic and fetal human tissues. Histochemistry 78:1–9. https://doi.org/10.1007/BF00491105CrossRefPubMed

Wagner J, Wickman E, DeRenzo C et al (2020) CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther 28:2320–2339. https://doi.org/10.1016/j.ymthe.2020.09.015CrossRefPubMedPubMedCentral

Wang Z, Wu Z, Liu Y et al (2017) New development in CAR-T cell therapy. J Hematol Oncol 10:53. https://doi.org/10.1186/s13045-017-0423-1CrossRefPubMedPubMedCentral

Wang Y, Chen M, Wu Z et al (2018) CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology 7:e1440169. https://doi.org/10.1080/2162402X.2018.1440169CrossRefPubMedPubMedCentral

Warneke V, Behrens H, Haag J et al (2013) Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis. Br J Cancer 109:2217–2227. https://doi.org/10.1038/bjc.2013.536CrossRefPubMedPubMedCentral

Webb GJ, Hirschfield GM, Lane PJ (2016) OX40, OX40L and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 50:312–332. https://doi.org/10.1007/s12016-015-8498-3CrossRefPubMed

Weissenstein U, Schumann A, Reif M et al (2012) Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer 12:206. https://doi.org/10.1186/1471-2407-12-206CrossRefPubMedPubMedCentral

Wickstroem K, Hagemann UB, Cruciani V et al (2019) Synergistic effect of a mesothelin-targeted 227Th conjugate in combination with DNA damage response inhibitors in ovarian cancer xenograft models. J Nucl Med 60:1293–1300. https://doi.org/10.2967/jnumed.118.223701CrossRefPubMedPubMedCentral

Wikenheiser DJ, Stumhofer JS (2016) ICOS co-stimulation: friend or foe? Front Immunol 7:304. https://doi.org/10.3389/fimmu.2016.00304CrossRefPubMedPubMedCentral

Wu Y, Liu Y, Huang Z et al (2021) Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat Biomed Eng 5:1336–1347. https://doi.org/10.1038/s41551-021-00779-wCrossRefPubMedPubMedCentral

Xia L, Zheng Z, Liu J et al (2020) EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo. Clin Transl Immunol 9:e1135. https://doi.org/10.1002/cti2.1135CrossRef

Xia L, Zheng Z, Liu J et al (2021) Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition targeting TNBC with EGFR CAR T cells and CDK7 inhibition. Cancer Immunol Res 9:707–722. https://doi.org/10.1158/2326-6066.CIR-20-0405CrossRefPubMed

Xie XF, Zhang QY, Huang JY et al (2023) Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial. Breast Cancer Res Treat 197:93–101. https://doi.org/10.1007/s10549-022-06770-6CrossRefPubMed

Yang P, Cao X, Cai H et al (2021a) The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol 360:104262. https://doi.org/10.1016/j.cellimm.2020.104262CrossRefPubMed

Yang Y, McCloskey JE, Yang H et al (2021b) Bispecific CAR T cells against EpCAM and inducible ICAM-1 overcome antigen heterogeneity and generate superior antitumor responses bispecific CAR T cells targeting EpCAM and ICAM-1. Cancer Immunol Res 9:1158–1174. https://doi.org/10.1158/2326-6066.CIR-21-0062CrossRefPubMedPubMedCentral

Yang YH, Liu JW, Lu C et al (2022) CAR-T cell therapy for breast cancer: from basic research to clinical application. Int J Biol Sci 18:2609. https://doi.org/10.7150/ijbs.70120CrossRefPubMedPubMedCentral

Ye B, Stary CM, Li X et al (2018) Engineering chimeric antigen receptor-T cells for cancer treatment. Mol Cancer 17:32. https://doi.org/10.1186/s12943-018-0814-0CrossRefPubMedPubMedCentral

Yeku OO, Brentjens RJ (2016) Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans 44:412–418. https://doi.org/10.1042/BST20150291CrossRefPubMedPubMedCentral

Yeku OO, Purdon TJ, Koneru M et al (2017) Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 7:10541. https://doi.org/10.1038/s41598-017-10940-8CrossRefPubMedPubMedCentral

Yin H, Xue W, Anderson DG (2019) CRISPR–Cas: a tool for cancer research and therapeutics. Nat Rev Clin Oncol 16:281–295. https://doi.org/10.1038/s41571-019-0166-8CrossRefPubMed

Yoon DH, Osborn MJ, Tolar J et al (2018) Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int J Mol Sci 19:340. https://doi.org/10.3390/ijms19020340CrossRefPubMedPubMedCentral

Yu IS, Cheung WY (2018) Metastatic colorectal cancer in the era of personalized medicine: a more tailored approach to systemic therapy. Can J Gastroenterol Hepatol 2018:9450754. https://doi.org/10.1155/2018/9450754CrossRefPubMedPubMedCentral

Zhang Y, Deng Z, Liao M et al (2012) Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma. Pathol Oncol Res 18:911–916. https://doi.org/10.1007/s12253-012-9521-0CrossRefPubMed

Zhang G, Wang L, Cui H et al (2014) Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep 4:3571. https://doi.org/10.1038/srep03571CrossRefPubMedPubMedCentral

Zhang C, Liu J, Zhong J et al (2017a) Engineering CAR-T cells. Biomark Res 5:22. https://doi.org/10.1186/s40364-017-0102-yCrossRefPubMedPubMedCentral

Zhang C, Wang Z, Yang Z et al (2017b) Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther 25:1248–1258. https://doi.org/10.1016/j.ymthe.2017.03.010CrossRefPubMedPubMedCentral

Zhang E, Yang P, Gu J et al (2018) Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol 11:102. https://doi.org/10.1186/s13045-018-0646-9CrossRefPubMedPubMedCentral

Zhang BL, Li D, Gong YL et al (2019) Preclinical evaluation of chimeric antigen receptor–modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer. Hum Gene Ther 30:402–412. https://doi.org/10.1089/hum.2018.229CrossRefPubMed

Zhou R, Yazdanifar M, Roy LD et al (2019) CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol 10:1149. https://doi.org/10.3389/fimmu.2019.01149CrossRefPubMedPubMedCentral

Zhou M, Chen M, Shi B et al (2022) Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling. Mol Ther 30:3379–3393. https://doi.org/10.1016/j.ymthe.2022.07.021CrossRefPubMedPubMedCentral

Titel: Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer
verfasst von: Yu Cao
Sergey K. Efetov
Mingze He
Yu Fu
Narasimha M. Beeraka
Jin Zhang
Xinliang Zhang
Namitha Bannimath
Kuo Chen
Publikationsdatum: 01.12.2023
Verlag: Springer International Publishing
Erschienen in: Archivum Immunologiae et Therapiae Experimentalis / Ausgabe 1/2023
Print ISSN: 0004-069X
Elektronische ISSN: 1661-4917
DOI: https://doi.org/10.1007/s00005-023-00684-x

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Activating NKG2C Receptor: Functional Characteristics and Current Strategies in Clinical Applications

Mast Cells and Resistance to Immunotherapy in Cancer

Heterogeneity of Extracellular Vesicles and Particles: Molecular Voxels in the Blood Borne “Hologram” of Organ Function, Disfunction and Cancer

Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products

The Pyroptotic and Nonpyroptotic Roles of Gasdermins in Modulating Cancer Progression and Their Perspectives on Cancer Therapeutics

Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?